Roth Iris 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Mar 2, 2023
Insider Transaction Report
Form 4
Roth Iris
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-03-01+297,500→ 297,500 totalExercise: $18.87Exp: 2033-03-01→ Common Stock (297,500 underlying) - Award
Common Stock
2023-03-01+52,500→ 52,500 total
Footnotes (2)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer.
- [F2]The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.